title: Reduction of plasma alanine aminotransferase during vigabatrin treatment.
abstract: In 9 drug-resistant patients with partial seizures treated with vigabatrin, gamma-vinyl GABA (VGB), alanine aminotransaminase (ALAT) activity in plasma was significantly reduced. Comparison of in vitro with in vivo measurements led us to conclude that this reduction is mainly an in vivo phenomenon, perhaps due to cross-enzyme inhibition. The assessment of two biological variables linked with ALAT, glucose and alanine levels under fasting conditions, failed to show any significant metabolic alterations. VGB is an effective drug for partial epilepsy. Our observations do not suggest that reduced ALAT activity is of clinical concern.
authors.affiliation: Department of Neurology, Institution de Lavigny, Switzerland.
authors.forename: G B
authors.initials: GB
authors.lastname: Foletti
authors.forename: M C
authors.initials: MC
authors.lastname: Delisle
authors.forename: C
authors.initials: C
authors.lastname: Bachmann
mesh_terms: D000293:Adolescent; D000328:Adult; D000409:Alanine / Q000097:blood; D000410:Alanine Transaminase / Q000097:blood*; D000927:Anticonvulsants / Q000097:blood / Q000627:therapeutic use*; D001786:Blood Glucose / Q000032:analysis; D004828:Epilepsies, Partial / Q000097:blood / Q000188:drug therapy*; D005215:Fasting; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D020888:Vigabatrin; D005680:gamma-Aminobutyric Acid / Q000031:analogs & derivatives* / Q000097:blood / Q000627:therapeutic use
chemical_list: D000927:Anticonvulsants; D001786:Blood Glucose; D005680:gamma-Aminobutyric Acid; D000410:Alanine Transaminase; D020888:Vigabatrin; D000409:Alanine